Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07322432 · ClinicalTrials.gov registry record · Phase 2
The CONQUER Trial - Cessation Of Nicotine, QUitting With E-cigarette Reduction
A Phase 2 study of Addiction Nicotine, sponsored by VapeAway.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
- 1
- Study location
NCT07322432 is a Phase 2 study of Addiction Nicotine that is actively recruiting participants, run by VapeAway. The registered enrollment target is 70 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07322432, a Phase 2 study of Addiction Nicotine, is actively recruiting participants, sponsored by VapeAway.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial evaluates the VapeAway system, a novel, multi-modal intervention designed to address the multifaceted nature of vaping addiction. VapeAway combines progressive nicotine tapering via proprietary filters, behavioral substitution with a sensory device (Fix Bar), and structured digital support. The purpose of this research is to evaluate the efficacy and safety of the investigational VapeAway system, a multi-component behavioral and nicotine-reduction intervention, for promoting cessation of nicotine-containing e-cigarette use in motivated adults. The primary objective is to determine if the VapeAway program can achieve a Continuous Abstinence Rate (CAR) of at least 25% at 30 days post-intervention completion, a rate which will be statistically compared to the historical spontaneous cessation rate of approximately 7%. Secondary objectives include assessing reductions in biochemical nicotine exposure (cotinine), vaping frequency, withdrawal symptoms, and electronic cigarette dependence, as well as characterizing the safety and tolerability profile of the intervention. Participants will be asked to follow the VapeAway system (filters, Fix Bar and timeout periods) as prescribed by the protocol for about 42 days. During this time, participants should keep track of vaping sessions throughout the trial.
Conditions Studied
Interventions
- DEVICE VapeAway filter system
Study Locations (1)
New York
- Prime Infusion - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2025-12-24 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07322432
The ClinicalTrials.gov registry entry for NCT07322432 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VapeAway, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Addiction Nicotine appearing as the primary indexed condition, and to 1 intervention - of which VapeAway filter system is the first listed.
NCT07322432 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT07322432 about?
NCT07322432 is a clinical study titled "The CONQUER Trial - Cessation Of Nicotine, QUitting With E-cigarette Reduction". This clinical trial evaluates the VapeAway system, a novel, multi-modal intervention designed to address the multifaceted nature of vaping addiction. VapeAway combines progressive nicotine tapering via proprietary filters, behavioral substitution with a sensory device (Fix Bar), and structured digit...
What is the current status of trial NCT07322432?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2025-12-24. Estimated completion is 2026-12.
What conditions does trial NCT07322432 study?
This clinical trial studies the following conditions: Addiction Nicotine.
What interventions are being tested in trial NCT07322432?
The interventions under investigation include: VapeAway filter system (DEVICE).
Who is sponsoring clinical trial NCT07322432?
This trial is sponsored by VapeAway, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07322432 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.